Form 8-K · Current Report · Filed 2026-08-05
AbbVie Inc. Announces Major Debt Offering
On August 4, 2026, AbbVie Inc. announced the issuance of various senior notes totaling approximately $9.93 billion in net proceeds. The offering includes floating rate notes and fixed-rate notes due between 2028 and 2066. The proceeds will be used to fund the acquisition of Apogee Therapeutics, Inc., pay related fees and expenses, and for other general corporate purposes. The sale of the notes is expected to close on August 18, 2026, subject to customary conditions.
- Filer
- AbbVie Inc. ABBV · NYSE
- Filed
- Accession
- 0001104659-26-091269
- CIK
- 0001551152
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$243.80
Since filing
+0.9%
Latest close
$246.11
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ABBV reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, ABBV insiders reported 2 Form 4 transactions — net buying of $49K.
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Never miss another ABBV filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.